Sugammadex Injection, Solution
Product Images NDC 16729-726

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Sugammadex (NDC 16729-726). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Accord Healthcare Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (80f46824 82f5 46e6 9e23 Fd4adbcea43d 01)

Chemical structure diagram of sugammadex, illustrating its cyclic molecular arrangement with multiple hydroxyl, sulfur, and carboxylate sodium groups.*

FDA Label Image

Chemical Structure (80f46824 82f5 46e6 9e23 Fd4adbcea43d 02)

Chemical structure diagram of sugammadex, showing the molecular ring with multiple hydroxyl (OH) groups, sodium (Na) carboxylate groups, and sulfur atoms as part of its complex cyclic oligosaccharide structure.*

FDA Label Image

Figure 1 (80f46824 82f5 46e6 9e23 Fd4adbcea43d 03)

A cumulative recovery rate graph comparing sugammadex 2 mg/kg and neostigmine 0.05 mg/kg over time to recovery in minutes. The x-axis represents time to recovery up to 120 minutes, and the y-axis shows cumulative recovery rate from 0 to 1. The graph includes median recovery times for sugammadex (1.4 minutes) and neostigmine (21.5 minutes), with quartiles noted. Sugammadex reaches near-complete recovery much faster than neostigmine.*

FDA Label Image

Figure 2 (80f46824 82f5 46e6 9e23 Fd4adbcea43d 04)

A cumulative recovery rate versus time to recovery (minutes) graph comparing sugammadex 2 mg/kg and neostigmine 0.05 mg/kg when used with vecuronium. The graph shows sugammadex achieves faster recovery, reaching near 100% cumulative recovery well before 20 minutes, while neostigmine approaches about 75% recovery by 120 minutes. Median recovery times are 2.1 minutes for sugammadex and 29.0 minutes for neostigmine.*

FDA Label Image

Principal Display Panel (2 mL Vial Carton)

Packaging label for Sugammadex Injection 200 mg/2 mL (100 mg/mL) by Accord Healthcare Inc. The label states the product is for intravenous use only and contains 10 single-dose 2 mL vials. The injection is described as a sterile, non-pyrogenic aqueous solution, clear to slightly yellow-brown. The label includes storage instructions, manufacturing information, and a barcode.*

FDA Label Image

Principal Display Panel (5 mL Vial Carton)

Packaging label for Sugammadex Injection 500 mg/5 mL (100 mg/mL) by Accord Healthcare Inc. for intravenous use. The label indicates a pack containing 10 single-dose 5 mL vials. It includes storage instructions, manufacturer details, and a barcode, with orange and black text on a white background.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.